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Melanin synthesis is a biologic property unique to the mela-
nocyte. It is highly elevated in malignant melanoma with the 
production of both cumelanin (brown/black pigment) and 
pheomelanin (yellow/red pigment), dihydroxyindole (DHI) 
and cysteinyldopa (CD), respectively, being major precur-
sors. Melanin metabolites are often released in the urine of 
patients with disseminated melanoma metastasis (melanuria). 
To establish a better method for the detection of occult mela-
noma this study compares the plasma levels of a pheomelanin 
metabolite, S-S-CD, and a eumelanin metabolite, 6-hy-
droxy-S-methoxyindole-2-carboxylic acid (6HSMI2C), in 
melanoma and non-melanoma patients and correlates them 
with tumor thickness and melanoma metastasis. We found a) 
that the normal plasma levels ofS-S-CD and 6HSM12C are 
less than 2.22 ng/ml and 1.04 ng/ml, respectively; b) that the 
group with the normal6HSMI2C plasma level does not have 
T he formation of melanin pigments (i.e., either the brown/black pigment of eumelanin or the yellow/ red pigment of pheomelanin) is a unique metabolic pathway for the melanocyte and is highly elevated in malignant melanoma (Fig 1) [1] . A significant num-
ber of reports have accumulated, indicating that the quantitation of 
melanin precursors/metabolites, especially a pheomelanin precur-
sor, 5-S-cysteinyldopa, in the urine and plasma (serum) may be of 
value in the detection of melanoma metastases [2-7]. The major 
obstacle for measurement of 5-S-CD, either in the plasma or urine 
form, is that it can also be released in normal healthy subjects and 
after UV exposure [8-15]. Plasma dopa may be increased in some 
patients with advanced melanoma metastases [16]. Dopa itself has, 
however, a very low renal plasma clearance, because it is decarboxy-
lated in the kidney, and determination of dopa in the urine is there-
fore of value only in advanced stages of melanoma [17] . Instead, 
quantitation of the urinary excretion of the dopa metabolites, dopa-
mine and 3, 4-dihydroxyphenyl-acetic acid (DOPAC) and their 
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any metastasis, whereas a normal S-S-CD level is seen in both 
non-melanoma and melanoma patients with and without 
metastasis; c) that a high plasma 6H5MI2C level is seen in all 
melanoma patients with tumor thickness more than 3.0 mm 
regardless of the presence or absence of metastasis, whereas in 
thinn.er melanoma patients this is seen only in positive me-
tastaSIS group; and d) that all melanoma patients with positive 
metastases showed a high plasma 6HSMI2C level (more than 
1.75 ng/ml). We conclude that the measurement of plasma 
levels of melanin metabolites provides a method for detecting 
occult melanoma metastasis and estimating the prognosis of 
melanoma patients, plasma 6HSMI2C level being more sen-
sitive and reliable than that of 5-S-CD, and its increased level 
being a high risk factor. Key words: melanoma/eumelanin/pheo-
melanin/metabolites. ] Il1vest Dermatol1 02:501-505, 1994 
methylated products, methoxytyrosine, homovanillic acid (HV A), 
and 4-hydroxy-3-methoxymandelic acid (VMA), was proposed for 
this purpo.se and tested to define the dopa turnover [18] . In spite of 
its potential usefulness for the diagnosis of advanced melanoma 
patients, the study indicated that other neural crest tumors (e.g., 
neuroblastoma) can also excrete DOPAC, HV A, VMA, and their 
conjugate in the urine [19]. 
Pavel et al introduced the measurement of indole metabolites in 
melanoma culture [20], and a number of studies have correlated the 
urin~ levels of indole derivatives, e.g., dihydroxyindole (DHI) 
and Its carboxylic form (DHICA), with melanoma progressions 
[21-24]. DHI and DHICA can be O-methylated in the liver as well 
as in melanoma cells. The O-methyl derivatives of DHI are then 
conjugated in the liver with glucuronic and sulfuric acid, and ex-
creted in the urine as the isomeric glucuronite and sulphate conju-
gates of 5-hydroxy-6-methoxyindole (5H6MI) and 6-hydroxy-5-
methoxyindole (6H5MI), and a 6-0-sulphate of DHI. In contrast, 
DHICA and its O-methyl derivatives, 5-hydroxy-6-methoxyin-
dole-2-carboxylic acid (5H6MI2C) and 6-hydroxy-5-methoxyin-
dole-2-carboxylic acid (6H5MI2C), can be released in the free form 
(Fig 1). In a recent experimental murine melanoma study, the 
plasma level of 5H6MI2C plus 6H5MI2C correlated to the tumor 
size [25]. 
To develop a better method for the detection of occult melanoma 
and establishment of prognostic criteria, this study measures the 
plasma levels of indole derivatives, i.e., O-methyl derivatives of 
DHICA (5H6MI2C and 6H5MI2C) and a thiol derivative (5-S-
CD), in melanoma and non-melanoma patients and compares their 
efficacy in estimating the prognosis of melanoma patients and in 
predicting the presence of occult melanoma metastases. 
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Figure L Metabolic pathway for the synthesis of melanin pigments, eumelanin, and pheomelanin. S-S-cysteinyldopa (S-S-CD) is a major precursor of 
pheomelanin synthesis whereas S,6-dihydroxyindole (5,6 DHI) and S,6-dihydroxyindole-2-carboxylic acid (5,6 DHI2C or DHICA) are eumelanin precur-
sors. DHICA is further O-methylated to form metabolites of S-hydroxy-6-methoxyindole-2-carboxylic acid (SH6MI2C) and 6-hydroxy-S-methoxyindole-
2-carboxylic acid (6HSMI2C). 
MATERIALS AND METHODS 
Subjects The following five groups cover a total of 88 subjects drawn 
from normal healthy volunteers and patients who visited the melanoma 
clinic at the Cross Cancer Institute at the University of Alberta: group A, 14 
cO'!trol specimens from 14 normal healthy subjects without a personal or 
family history of cancer, including malignant melanoma; group B, 10 con-
trol specimens from 10 patients with systemic development of non-mela-
noma cancers; group C, 26 specimens from 21 patients who had cutaneous 
melanoma with no evidence of metastases (as judged by conventional rou-
tine methods such as X-ray, ultrasound of abdomen, pelvis, CTscan of head, 
and bone scanning) at the time of plasma collection; group D, 24 specimens 
from 16 patients who had cutaneous melanoma with metastases in the past, 
but were disease free at the time of plasma collection; and group E, 14 
specimens from 10 patients who had cutaneous melanoma with metastases at 
the time of plasma collection. Among 47 melanoma patients entered in this 
study, nine cases were of unknown primary melanomas, and measurement of 
tumor thickness was not availab le for 13 cases. Test plasma samples were 
obtained after the surgery, and patients were followed up every 3 months for 
the first 2 years and every 6 months thereafter up to 5 years. On each visit, 
blood samples were obtained and a chest X-ray was taken. Ultrasound studies 
were done on every second visit. If there was any suspicious metastatic lesion 
on chest X-ray and ultrasound examination, or from the finding of plasma 
melanin metabolites, further investigations, e.g., CT and bone scanning, 
were carried out. The staging of melanoma patients followed the pTNM 
classification of the American Joint Committee on Cancer [26]. Tumor 
thickness was measured by Breslow's classification [27]. 
Analysis of Plasma 5-S-CD Fifty milligrams of acid-washed alumina 
and 100 III of 2% sodium metabisulfite were applied in an Eppendorf tube 
(1.5 ml volume). In addition, 10 III of a-methyl-dopa (0.2I1g/ml) was 
included in hydrochloric acid (0.1 moljl) as an internal standard. The 1.0 ml 
of test plasma or 1.0 ml of 1 % ethylene diamine tetraacetic acid (EDT A) . 2 
Na and 10111 of standard solution containing L-dopa and dopamine, each 0.1 
I1g/ml, and S-S-CD, 0.2I1g/ml in hydrochloric acid (0.1 moljl) were then 
added to this tube. Catechols were absorbed onto alumina by adding 2.7 
mol/I Tris-HCI buffer - 2% EDTA . 2 Na(pH 8.6) . After centrifugation, 
alumina was washed twice with 1 ml of water. 
Catcchols were eluted with 100 111 of perchloric acid (0.4 mol/I) by 
mixing for 2 min. After centrifugation, 10 - 20 III of supernatant was injected 
into the high-performance liquid chromatograph (HPLC). Catechols con-
tained in this sample were quantified from the relative ratio of peak height 
using dopa, dopamine, S-S-CD, and a-methyl-dopa as standards. 
Analysis of Plasma 5H6MI2C and 6H5MI2C One milliliter of plasma 
was saturated with 100 mg of sodium ch loride and hydrochloric acid (1 
moljl). The mixture was then extracted twice with 5 ml of ethyl acetate by 
shaking for 2 min and centrifugation. The pooled ethyl acetate extracts were 
evaporated at 40° C under vacuum and the residue was eluted with 200111 of 
mobile phase. 
HPLC Chromatography A high-performance liquid chromatograph 
(Waters, model 600 E, Millford , MA) was employed with a Waters 460 
electrochemical detector, as follows. 
The AIJalysis oj 5-S-CD: The detector was set at 750 mY. Separation was 
achieved by a reverse-phase chromatography (11 BONDAPAK C18 lScm, 
Waters) at 25°C. The mobile phase contained 0.1 M phosphoric acid (1 2 
g/I) , 0.1 M methanesulfonic acid (10 g/l), and 0.1 mM EDT A . 2 Na in 
water, pH being adjusted to 3.1. The flow rate was 1.0 ml/rnin. 
Tile Analysis oj Iudoles: The detector was set at 600 mY using the same 
reverse-phase chromatography (11 BONDAPAK C18 25 cm, Waters). The 
mobile phase contained 0.1 M potassium phosphate buffer at pH 2.5 con-
taining 1 mM EDT A . 2 Na and methanol (80: 20 in v /v). The column was 
maintained at 60°C. The flow rate was 1.0 ml/min. 
RESULTS 
Determination of 5H6MI2C and 6H5MI2C in Plasma 
Samples On HPLC chromatograms SH6MI2C and 6HSMI2C 
were eluted at 6.7 and 8.2 min, respectively. There were, however, 
unknown peaks that were eluted occasionally at the same position of 
SH6MI2C elution, causing the measurement of SH6MI2C to be 
unreliable. Further analysis was carried out only on 6HSMI2C. 
Plasma Levels of 5-S-CD and 6H5MI2C in Normal Subjects 
and Non-melanoma Cancer Patients Plasma samples from 14 
normal subjects (group A) were analyzed. The mean plasma con-
centrations (±SD) of S-S-CD and 6HSMI2C were 1.71 ± 0.51 
ng/ml and 0.51 ± 0.53 ng/ml, respectively. We defined the nor-
mal plasma level of 5-S-CD and 6HSMI2C as less than 2 .22 ng/m1 
and 1.04 ng/ml, respectively. Plasma levels of S-S-CD and 
6HSMI2C in patients with non-melanoma cancer (group B) were 
2.15 ± 0.66 ng/ml and 0.56 ± 0.36 ng/ml, respectively. These 
values were not significantly different from those of control subjects 
(group A) (Fig 2a,b). 
VOL. 102, NO.4 APRIL 1994 
a 
0 
b 
Group 
A 
Group 
A 
B 
B 
• 
• 
c o E 
• 
• 
• 
• 
• 
y 
C 0 E 
Figure 2. Comparison of plasma level of 5-S-CD and 6H5MI2C in mela-
noma patients with and without metastasis. a) 5-S-CD level: A) 1.71 ± 0.51 
ng/ml in group A normal healthy volunteers; B) 2.15±0.66 ng/ml in group 
B patients with non-melanoma cancers; C) 3.37 ± 2.58 ng/ml in group C 
patients with no. metastasis in the past and the present; D) 2.65 ± 1.62 n~l.ml 
in group D patients With negatIve metastasIs at the present, but positive 
metastasis in the past; E) 5.62 ± 4.71 ng/ml in group E patients with 
metastasis by routine laboratory examinations (e.g., chest X-ray, ultrasound, 
CT scan, and bone scan). by 6H5MI2C: A) 0.51 ± 0.53 ng/ml in group A 
normal healthy volunteers; B) 0.56 ± 0.36 ng/ml in group B patients with 
non-melanoma cancers; C) 1.61 ± 2.57 ng/ml in group C patients with no 
metastasis in the past and the present; D) 1.81 ± 1.67 ng/ml in group D 
patients with metastasis in the past, but negative one at the time of blood 
collection; E) 4.09 ± 5.35 ng/ml in group E patients with metastases. 
Tumor Thickness and plasma Level of 5-S-CD and 
6H5MI2C in Melanoma Patients Group C, 0, and E mela-
noma patients were analyzed. Table I summarizes the relationship 
between plasma levels of 5-S-CD and 6H5MI2C and the tumor 
thickness and positive versus negative metastases of melanoma. The 
definition of positive versus negative melanoma metastasis was 
based upon a minimum of 12-month follow-up of individual cases, 
with clinical observations and laboratory tests, including chest 
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X-ray, ultrasound, CT scan, and bone scan. No significant differ-
ence and correlation to the tumor thickness were noted in the indi-
vidual four groups for measurement of plasma 5-S-CD level. In 
contrast, the plasma level of 6H5MI2C showed a significant differ-
ence depending upon the tumor thickness. The melanoma groups 1 
and 2 with tumor thickness less than 1.0 mm and 2.0 mm, respec-
tively, did not show any increase of the plasma 6H5MI2C level. 
Importantly, however, there was a tendency towards a higher 
plasma 6H5MI2C level being in a positive metastasis group, even in 
those thin-melanoma groups. Group 3 and 4 participants with a 
tumor thickness of more than 2.0 mm and 3.0 mm, respectively, 
revealed significant and marked increases in the plasma levels of 
6H5MI2C as compared to those of control subjects, and to groups 1 
and 2 without metastases (Table I). Specifically, the latter group 4 
(more than 3.0 mm) showed at least a threefold increase, as com-
pared to normal control and non-melanoma cancer subjects (p < 
0.001) in the plasma 6H5MI2C level and 74% of these patients had 
the melanoma metastases either at the time of sample collection 
(68%) or in the past (6%). Similarly, in group 3 (patients with tumor 
thickness of between 2.0 and 3.0 mm), 42% of the participants had 
melanoma metastases either at the time of plasma collection (25%) 
or in the past (17%). The findings indicate that the plasma 
6H5MI2C level , but not 5-S-CD level, correlates well with the 
tumor thickness (in particular, > 2.0 mm), and a high risk of 
having metastatic melanoma . 
plasma Level of 5-S-CD and 6H5MI2C, and Melanoma 
Stages Table II compares the plasma levels of 5-S-CD and 
6H5MI2C with melanoma stages (I - IV development) . In stage I 
melanoma, none of the patients revealed an increased level of 
6H5MI2C as compared to that of control subjects. Melanoma pa-
tients in stages I - IV had a significant increase in the plasma level of 
5-S-CD. However, there was no correlation between the increased 
5-S-CD plasma level and melanoma stages, e.g., stage II group had a 
higher level than stage III. In contrast, a more significant difference 
was seen in the plasma 6H5MI2C level, in parallel to melanoma 
stages and metastases. There was no increase in plasma 6H5MI2C 
level in stage I patients, its mean being 0.38 ng/ml. In contrast, 
those patients in stages II, III, and IV who have either melanoma 
metastases or high tumor thickness showed a high plasma 
6H5MI2c; level.. Importantly, 6H5MI2C levels of stage IV patients 
were 10 times higher than those of stage I patients. 
plasma Levels of 5-S-CD and 6H5MI2C in Melanoma Pa-
tients With and Without Metastasis The plasma levels of 5-S-
CD and 6H5MI2C were compared with respect to the presence or 
absence of melanoma metastases (Fig 2a,b). As stated earlier, the 
mean plasma levels of 5-S-CD and 6H5MI2C in nOfmal control and 
non-melanoma patients were 1.71 and 2.15 ng/ml, and 0.51 and 
0.56 ng/ml, respectively. A marked increase in the plasma level of 
both 5-S-CD and 6H5MI2C was seen in melanoma patients with 
metastases (p < 0.001), its mean 5-S-CD and 6H5MI2C levels 
being 5.62 and 4.09 ng/ml, respectively. Melanoma patients with 
metastases (group E) always showed a plasma 6H5MI2C level much 
higher than that of control subjects and non-melanoma cancer pa-
tients, as well as those melanoma patients without metastases in the 
past or at the time of plasma collection, whereas the same group of 
patients often revealed a plasma 5-S-CD level lower than that of 
control. Melanoma patients in disease-free states at the time of sam-
ple collection, i.e., either without metastases (group C) Of with 
positive metastases in the past (group D), indicated the mean value 
of the plasma 6H5MI2C at less than 1.8 ng/ml. When the group C 
patients (no metastases in the past) showed a high plasma 6H5MI2C 
level (> 2.0 ng/ml), they lISually revealed a high tumor thickness, 
more than 2.0 mm (2.0 < 3.0 mm = 40%; > 3.0 mm = 60%). In 
contrast, SlIch a clear correlation with the tumor thickness or the 
presence of melanoma metastasis was not seen in the group C pa-
tients with high plasma 5-S-CD levels. One patient (a 70-year-old 
man; tumor thickness unknown) in group C was shown by routine 
chest X-ray examination to have a diffuse osteosclerotic lesion 
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Table I. Plasma Level of 5-S-Cysteinyldopa (5-S-CD) and 6-Hydroxy-5-Methoxy-Indole 2-Carboxylic Acid (6H5MI2C) , 
Positive Versus Negative Metastases, and Tumor Thickness of Melanomas 
5-S-CD 6H5MI2C 
Percent Distribution of Subjects 
Negative Positive Negative Positive 
Number Metastasis Metastasis Metastasis Metastasis 
Tumor of Negative Positive Level p Level p Level p Level p 
Thickness Subjects Metastasis' Metastasisb (ng/m1)' Value (ng/ml)' Value (ng/ml)' Value (ng/ml)' Value 
< 1.0 11 64 36 2.24 ± 0.89 N,S'" 5.69 ± 2.53 P < 0.001' 0.41 ± 0.35 N,S'" 1.24 ± 1.81 N,S'" 
1.0 < 2.0 9 67 33 2.35 ± 1.82 N,S 7.17 ± 4.21 p < 0.001 0.90 ± 1.66 N,S 0.82 ± 0.88 N,S 
2.0 < 3.0 12 58 42 4.38 ± 1.91 N,S 1.78 ± 1.12 N,S 1.76 ± 2.07 P < 0.05 4.49 ± 1.65 P < 0.001 
3.0 < 19 26 74 3.39 ± 1.57 P < 0.001 3.75 ± 3.44 N,S 2.38 ± 1.76 P < 0.001 2.17 ± 1.18 P < 0.001 
• Percent distribution of group C melanoma patients who do not have any visible metastasis . 
• Percent distribution of group D and E melanoma patients. Group D patients bave a past history of melanoma metastasis, but no detectable metastasis at the time of plasma 
collection as judged by routine conventional methods, e.g., chest X-ray, ultrasound of abdomen, pelvis, and CT scan of the head, and Gc-bone scintigraphy. Group E melanoma 
patients have metastasis at the time of plasma collection. 
, ng/ml of mean ± SD. 
J Not significant in t test. . 
'Comparison with normal control subjects, their mean ± SD being 1.17 ± 0.51 ng/ml and 0.51 ± 0.53 ng/ml in 5-S-CD and 6H5M12C, respectively. 
throughout the bony thorax due to melanoma metastasis. The 
plasma 5-S-CD and 6H5MI2C levels were measured and all three 
measurements showed a normal value of 6H5MI2C (0.44-
0.52 ng/ml) but an increased level of 5-S-CD (2.47 -4.44 ng/ml). 
The patient was subsequently found to have a bone metastasis of a 
prostate carcinoma, but none of melanoma metastasis, and died 2 
years later of prostate carcinoma metastasis. In group D, with the 
exception of one case, the patients who had a plasma 6H5MI2C 
level higher than 2.0 ng/ml showed a tumor thickness of more than 
3.0 mm, indicating that they are at high risk for metastases. Three 
of the group D patients showed lung metastases 3 months later, 
even though the tumor thickness of their primary melanoma was 
less than 0.75 mm and there was no visible melanoma metastasis on 
chest X-ray examination at the time of plasma collection. One 
patient in group E (a 47-year-old man; 1.35-mm tumor thickness) 
developed a tumor mass at the site of skin graft and lymph node 
swelling 2 years after melanoma excision. Three repeated biopsy 
reports of both subcutaneous tumors and lymph nodes indicated the 
simple fibrosis with negative immunostaining of all of the mela-
noma markers tested. However, of the two, the plasma 5-S-CD and 
6H5MI2C levels revealed a marked increase. Importantly, the rou-
tine laboratory investigations, including chest x-ray, ultrasound of 
abdomen, CT scan of head, and bone scan, failed to demonstrate the 
presence of melanoma metastases. However, the plasma level of 
6H5MI2C (21.74 ng/ml) was much higher than that of 5-S-CD 
(9.35 ng/ml), and the patient showed (3 months later) visible pul-
monary and brain melanoma metastases on chest X-ray and CT 
scan; he died 6 months later. These findings may again indicate that 
the quantitation of plasma 6H5MI2C levels may be more reliable 
than that of plasma 5-S-CD levels. A patient with a high plasma 
6H5MI2C level most likely has melanoma metastasis even though 
it has not yet been identified by conventional, routine tests , e.g. , 
chest X-ray and ultrasound. 
DISCUSSION 
Among various melanin metabolites, 5-S-CD, a major pheomelanin 
precursor, is a marker that has been used commonly for analysis of 
melanoma metastasis. Our previous HPLC study, however, intro-
duced the importance of measuring the urinary indole eumelanin 
metabolites, a combination of 6H5MI2C and 5H6MI2C, plus the 
5-S-CD pheomelanin measurement rather than the latter alone 
[22]. The urinary and plasma levels of 5-S-CD in normal healthy 
subjects have been shown to possess large physiologic variations 
[8,17], often resulting in significant false results in the analysis of 
melanoma metastasis. 5-S-CD may not just be a precursor of ph eo-
melanin. Along with others, we have previously reported the pres-
ence of free and protein-bound 5-S-CD in non-melanocytic organs 
and tissues in mice, rats, and guinea pigs [28 ,29]. In addition, after 
UV exposure new melanin pigmentation occurs and there is in-
creased 5-S-CD excretion [12-15]. 5-S-CD is excreted in patients 
suffering from both tyrosinase-positive and negative albinisms, the 
latter of which does not have any melanin synthesis [30]. 
In this study we found the normal range of the plasma 6H5M 12C 
concentration to be 0.07-2.15 ng/ml (0.32-9.90 nmol/I; mean 
value, 0.51 ng/ml, 2.35 nmol/I). This mean value was slightly 
lower than that (3 .6 nmol/I) reported recently in normal Oriental 
subjects [24]. Importantly, we found that the plasma 6H5M12C 
level correlates well with the tumor thickness, melanoma stage, and 
melanoma metastases. The increased plasma 6H5M12C concentra-
tion was seen in melanoma patient groups with tumor thickness of 
more than 2.0 mm and 3.0 mm, and in stages II, III, and IV, indicat-
ing that cases with a high plasma 6H5MI2C level are at high risk for 
Table II. Plasma Levels of 5-S-CD and 6H5MI2C in Different Stages of Melanoma Patients 
Percent Distribution of Subjects 5-S-CD 6H5MI2C 
Melanoma Number of Metastasis Metastasis Metastasis Plasma p Plasma p 
Stage Subjects None' Pasrb Present< Level' (ng/ml) Value Level' (ng/ml) Value 
I 8 100 0 0 2.18 ± 1.00 <0.021' 0.38 ± 0.34 NS'J 
II 18 100 0 0 3.50 ± 1.98 < 0.001 1.38 ± 1.55 <0.05 
III 15 13 87 0 2.59 ± 1.73 < 0.02 1.97 ± 1.13 < 0.02 
IV 30 0 47 53 4.54 ± 3.96 < 0.01 3.26 ± 3.97 < 0.01 
• Group C melanoma patients with no metastasis. 
• Group 0 melanoma patients with metastasis in the past, but no metastasis detectable at the time of sample collection as judged by routine diagnostic protocols of chest X-ray, 
ultrasound of abdomen, pelvis, and scalp, Ga-bone scintigraphy. 
, Group E melanoma patients with metastases at the time of sample collection. 
J ng/ml of mean ± SD. 
t N ot significant in t test. 
f Compared with normal healthy subjects, their means ± SD being 1.71 ± 0.52 ng/ml and 0.51 ± 0.53 ng/ml in 5-S-CD and 6H5MI2C, respectively. 
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the development of metastases, a visible metastasis, or a hidden 
non-visible melanoma metastasis that has not yet been identified by 
routine diagnostic methods. 
In this study, 6HSMI2C was chosen over 5H6MI2C to measure 
the plasma indole metabolites as a melanoma-metastasis marker be-
cause the HPLC peak of 5H6MI2C was masked by unknown peaks 
and the ratio of absorption peaks of 5H6MI2C and 6H5MI2C was 
approximately equal. A number of eu- and pheomelanin-related 
metabolites were recently measured in the urine of people with 
various capacities for melanin synthesis. 5H6MIC was found to be 
the best urinary marker of melanin pigmentation in the skin [31] . In 
that study, however, 6HSMI2C was not tested, though S-S-CD and 
other indole metabolites were compared. Another recent study, 
which measured the plasma and urinary levels of 5-S-CD and 
6HSMI2C plus 5H6MI2C in B16-melanoma-bearing mice, indi-
cated an excellent correlation between the plasma concentration of 
SH6MI2C plus 6H5MI2C and 5-S-CD, whereas the urinary excre-
tion of 5H6MI2C plus 6H5MI2C and 5-S-CD showed no signifi-
cant correlation [25]. The enzyme catechol O-methyltransferase 
has a broad spectrum of physiologic and pharmacologic roles in 
humans [32,33]. In melanoma cells, this O-methylation prevents 
the formation of highly reactive O-quinones and, hence, the 
production of indole metabolites. Therefore, 6H5MI2C and 
SH6MI2C could be a part of the mechanisms to protect the cells 
against their own toxic products [20]. A high plasma 6H5MI2C 
level in certain melanoma patients who did not have any melanoma 
metastasis may be attributable to this antioxidant process. 
The diagnosis of occult melanoma metastasis is a serious medical 
problem. Spontaneous regression of primary cutaneous melanoma 
occurs fairly frequently and 3.6-15.0% of melanoma patients seek 
their medical advice for unknown primary lesions [34] . There is no 
tumor thickness of primary melanoma available. Even when a sec-
ondary lesion is removed, it is not presently possible to determine 
whether these patients have another hidden secondary melanoma. 
Our measurement of the plasma eumelanin metabolite 6H5MI2C, 
combined with the 5-S-CD pheomelanin measurement would 
likely provide a sensitive method for this purpose and therefore 
should not lose its usefulness. This measurement would also help to 
judge the effect of chemotherapeutic and other treatment mo-
dalities. 
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